PT835663E - Vacinas combinadas compreendendo o antigénio de superfície da hepatite b e outros antigénios - Google Patents

Vacinas combinadas compreendendo o antigénio de superfície da hepatite b e outros antigénios Download PDF

Info

Publication number
PT835663E
PT835663E PT97204034T PT97204034T PT835663E PT 835663 E PT835663 E PT 835663E PT 97204034 T PT97204034 T PT 97204034T PT 97204034 T PT97204034 T PT 97204034T PT 835663 E PT835663 E PT 835663E
Authority
PT
Portugal
Prior art keywords
hepatitis
antigens
surface antigen
combined vaccines
vaccines
Prior art date
Application number
PT97204034T
Other languages
English (en)
Inventor
Pierre Hauser
Jean Petre
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26300928&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT835663(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB929211081A external-priority patent/GB9211081D0/en
Priority claimed from GB929213308A external-priority patent/GB9213308D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of PT835663E publication Critical patent/PT835663E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0017—Combination vaccines based on whole cell diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
PT97204034T 1992-05-23 1993-05-15 Vacinas combinadas compreendendo o antigénio de superfície da hepatite b e outros antigénios PT835663E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929211081A GB9211081D0 (en) 1992-05-23 1992-05-23 Vaccines
GB929213308A GB9213308D0 (en) 1992-06-23 1992-06-23 Vaccine

Publications (1)

Publication Number Publication Date
PT835663E true PT835663E (pt) 2010-01-04

Family

ID=26300928

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97204034T PT835663E (pt) 1992-05-23 1993-05-15 Vacinas combinadas compreendendo o antigénio de superfície da hepatite b e outros antigénios

Country Status (31)

Country Link
US (1) US6013264A (pt)
EP (4) EP2289548A3 (pt)
JP (1) JP3626996B2 (pt)
KR (1) KR100287083B1 (pt)
CN (2) CN1136918C (pt)
AP (1) AP567A (pt)
AT (2) ATE168271T1 (pt)
AU (5) AU4315693A (pt)
CA (1) CA2136429C (pt)
CY (1) CY2614B2 (pt)
CZ (1) CZ283910B6 (pt)
DE (4) DE69319728T2 (pt)
DK (2) DK0642355T3 (pt)
ES (2) ES2334181T3 (pt)
FI (1) FI945483A (pt)
HK (2) HK1021142A1 (pt)
HU (1) HU220236B (pt)
IL (1) IL105770A (pt)
LU (2) LU91658I2 (pt)
MA (1) MA22894A1 (pt)
MX (1) MX9302982A (pt)
MY (1) MY110665A (pt)
NO (1) NO309675B1 (pt)
NZ (1) NZ253065A (pt)
PT (1) PT835663E (pt)
RU (1) RU2160120C2 (pt)
SG (1) SG48365A1 (pt)
SI (1) SI9300271A (pt)
SK (1) SK280702B6 (pt)
UA (1) UA40596C2 (pt)
WO (1) WO1993024148A1 (pt)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9503863D0 (en) * 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions
US6696065B1 (en) 1995-05-04 2004-02-24 Aventis Pastuer Limited Acellular pertussis vaccines and methods of preparation thereof
FR2734484B1 (fr) 1995-05-24 1997-06-27 Pasteur Merieux Serums Vacc Composition vaccinale liquide et procede de fabrication
US20030157129A1 (en) * 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
US20020054884A1 (en) 1995-06-23 2002-05-09 Smithkline Beecham Biologicals, Sa Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
PL184872B1 (pl) 1995-06-23 2003-01-31 Smithkline Beecham Biolog Kombinowana szczepionkaĆ zestaw do przygotowania kombinowanej szczepionkiĆ sposób wytwarzania kombinowanej szczepionki i jej zastosowanie
CA2259415A1 (en) * 1996-07-02 1998-01-08 Connaught Laboratories Limited Multivalent dtp-polio vaccines
US20010014331A1 (en) 1996-11-07 2001-08-16 Smithkline Beecham Biologicals S.A. Acellular pertussis vaccine with diphthriae-and tetanus-toxoids
GB9623233D0 (en) * 1996-11-07 1997-01-08 Smithkline Beecham Biolog Vaccine composition
CU22629A1 (es) * 1997-03-06 2000-12-22 Ct Ingenieria Genetica Biotech Formulaciones inmunopotenciadoras para uso vacunal
EP0980257A1 (en) * 1997-05-01 2000-02-23 Chiron Corporation Use of virus-like particles as adjuvants
BR9714980A (pt) * 1997-09-15 2001-11-06 Pasteur Merieux Msd Vacinas multivalentes
HUP0101047A3 (en) * 1998-03-09 2004-10-28 Smithkline Beecham Biolog Combined vaccine compositions
GB9806456D0 (en) * 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
GB9809507D0 (en) * 1998-05-01 1998-07-01 Smithkline Beecham Biolog Novel composition
US20030049268A1 (en) 1998-05-01 2003-03-13 Smithkline Beecham Biologicals S.A. Novel composition
RU2130778C1 (ru) * 1998-07-31 1999-05-27 Акционерное общество закрытого типа НПК "Комбиотех Лтд" Комбинированная вакцина для иммунопрофилактики вирусного гепатита в, столбняка, дифтерии и коклюша
RU2130779C1 (ru) * 1998-07-31 1999-05-27 Акционерное общество закрытого типа Научно-производственная компания "Комбиотех Лтд" Комбинированная вакцина для иммунопрофилактики вирусного гепатита в, столбняка и дифтерии
AT408615B (de) * 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
AU750587B2 (en) 1998-10-16 2002-07-25 Smithkline Beecham Biologicals (Sa) Adjuvant systems and vaccines
CN1053590C (zh) * 1998-10-19 2000-06-21 卫生部长春生物制品研究所 冻干甲型肝炎减毒活疫苗及其保护剂
CU22871A1 (es) * 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
US6974581B1 (en) * 1998-12-15 2005-12-13 Aventis Pasteur Limited Multi-component vaccine comprising at least two antigens from haemophilus influenzae to protect against disease
US7098309B2 (en) * 1998-12-23 2006-08-29 Merck & Co., Inc. Recombinant hepatitis B surface antigen
US7172762B1 (en) * 1999-01-29 2007-02-06 Pfizer Inc. Erysipelothrix rhusiopathiae antigens and vaccine compositions
GB9923060D0 (en) 1999-09-29 1999-12-01 Chiron Spa Vaccine
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
KR100374813B1 (ko) * 2000-04-07 2003-03-03 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드, 정제백일해 및비형간염표면항원을 포함한 4가 혼합백신 및 그 제조 방법
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
SK288007B6 (sk) 2000-06-29 2012-10-02 Glaxosmithkline Biologicals S. A. Multivalent vaccine composition, process for its producing, and its use
KR100385711B1 (ko) * 2000-07-05 2003-05-27 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드와 백일해균 및ｂ형간염표면항원을 포함한 4가 혼합백신 및 그 제조방법
KR100401423B1 (ko) * 2001-01-10 2003-10-17 주식회사 엘지생명과학 혼합 백신의 제조 방법
MXPA03006561A (es) 2001-01-23 2004-10-15 Aventis Pasteur Vacuna del conjugado proteina-polisacarido meningococico, multivalente.
AU2007200116A1 (en) * 2001-04-03 2007-02-01 Glaxosmithkline Biologicals S.A. Vaccine composition
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
RU2323002C2 (ru) * 2001-07-26 2008-04-27 Чирон Срл. Вакцины, содержащие алюминиевые адъюванты и гистидин
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
IL145926A0 (en) 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
CU23031A1 (es) * 2002-01-24 2005-02-23 Ct Ingenieria Genetica Biotech Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
ATE538808T1 (de) * 2002-03-28 2012-01-15 Brenntag Biosector As Kombinierte dns/protein impfstoffzusammensetzungen
GB0223355D0 (en) * 2002-10-08 2002-11-13 Chiron Spa Vaccine
ES2280809T3 (es) 2002-11-01 2007-09-16 Glaxosmithkline Biologicals S.A. Composicion inmunogenica.
EP2191844B1 (en) 2003-01-30 2014-03-05 Novartis AG Injectable vaccines against multiple meningococcal serogroups
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
CN103405761A (zh) 2003-10-02 2013-11-27 诺华疫苗和诊断有限公司 多种脑膜炎球菌血清群的液体疫苗
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
CN1984679B (zh) 2004-06-04 2013-05-15 美国政府健康及人类服务部 制备免疫原性结合物的方法
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
BRPI0610297A2 (pt) 2005-04-18 2010-06-08 Novartis Vaccines & Diagnostic expressão de antìgeno de superfìcie de vìrus da hepatite b para a preparação de vacina
US9931397B2 (en) 2005-06-27 2018-04-03 Glaxosmithkline Biologicals S.A. Immunogenic composition
GB0517719D0 (en) * 2005-08-31 2005-10-05 Chiron Srl Vaccines containing pili
JP5135220B2 (ja) 2005-09-01 2013-02-06 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 血清群ｃ髄膜炎菌を含む複数ワクチン接種
GB0522765D0 (en) * 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
EP1862176A1 (de) * 2006-05-31 2007-12-05 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Ein Verfahren zur Herstellung einer Impfzusammensetzung
EP1862177A1 (de) * 2006-06-01 2007-12-05 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Ein Verfahren zur Herstellung einer Impfzusammensetzung
GB0616226D0 (en) * 2006-08-15 2006-09-27 Novartis Ag Processes
GB0616306D0 (en) * 2006-08-16 2006-09-27 Novartis Ag Vaccines
GB0617602D0 (en) * 2006-09-07 2006-10-18 Glaxosmithkline Biolog Sa Vaccine
PT2097102E (pt) 2006-09-07 2012-08-03 Glaxosmithkline Biolog Sa Vacina de combinação tendo quantidades reduzidas de antigénio de poliovírus
CA2677455A1 (en) * 2007-02-07 2008-08-14 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Recombinant antigens of human cytomegalovirus (hcmv)
US20100074918A1 (en) 2007-05-02 2010-03-25 Jan Poolman Vaccine
PE20100365A1 (es) * 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion
PE20100366A1 (es) * 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
IT1398927B1 (it) 2009-06-25 2013-03-28 Consorzio Interuniversitario Per Lo Sviluppo Dei Sistemi A Grande Interfase Csgi Espressione batterica di un gene artificiale per la produzione di crm197 e derivati.
GB0917647D0 (en) 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
US20130071422A1 (en) 2010-03-18 2013-03-21 Michele Pallaoro Adjuvanted vaccines for serogroup b meningococcus
FR2966044B1 (fr) 2010-10-18 2012-11-02 Sanofi Pasteur Procede de conditionnement d'un vaccin contenant un adjuvant d'aluminium
EP2646459B1 (en) 2010-12-02 2020-01-08 Bionor Immuno AS Peptide scaffold design
EP2661277A2 (en) 2011-01-05 2013-11-13 Bharat Biotech International Limited A combination heptavalent vaccine
EP3338798A1 (en) 2011-01-06 2018-06-27 Bionor Immuno AS Multimeric peptide
GB201105981D0 (en) 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
EP2707024A4 (en) * 2011-05-11 2015-03-04 Riesbeck Healthcare Sweden Ab PROTEIN F - A NEW HAEMOPHILUS INFLUENZAE ADHESINE WITH LAMININ AND VITRONECTIN BINDING CHARACTERISTICS
WO2013049535A2 (en) 2011-09-30 2013-04-04 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Influenza vaccine
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
DE102011118371B4 (de) 2011-11-11 2014-02-13 Novartis Ag Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
DE102011122891B4 (de) 2011-11-11 2014-12-24 Novartis Ag Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
EP2592137A1 (en) 2011-11-11 2013-05-15 Novartis AG Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
FR2985663B1 (fr) * 2012-01-17 2015-03-27 Sanofi Pasteur Procede de formulation d'un vaccin contenant au moins deux antigenes susceptibles de s'adsorber sur de l'oxy hydroxyde d'aluminium
ES2653261T3 (es) 2012-02-01 2018-02-06 Glaxosmithkline Biologicals S.A. Procedimiento de fermentación
EP2822584A1 (en) * 2012-03-08 2015-01-14 Novartis AG Combination vaccines with tlr4 agonists
WO2013182661A1 (en) 2012-06-06 2013-12-12 Bionor Immuno As Peptides derived from viral proteins for use as immunogens and dosage reactants
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
JP2015525794A (ja) 2012-08-06 2015-09-07 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 乳児においてｒｓｖ及び百日咳菌に対する免疫応答を惹起するための方法
CA2886938A1 (en) 2012-10-12 2014-04-17 Glaxosmithkline Biologicals S.A. Non-cross-linked acellular pertussis antigens for use in combination vaccines
MX362793B (es) 2013-03-08 2019-02-13 Janssen Vaccines & Prevention Bv Vacuna acelular contra pertussis.
WO2014164727A1 (en) 2013-03-12 2014-10-09 Wisconsin Alumni Research Foundation A method of treating fungal infection
BE1022008B1 (fr) 2013-08-05 2016-02-03 Glaxosmithkline Biologicals S.A. Compositions immunogenes combinees
AR101256A1 (es) 2014-07-21 2016-12-07 Sanofi Pasteur Composición vacunal que comprende ipv y ciclodextrinas
MA52400B1 (fr) * 2015-09-16 2023-01-31 Lg Chemical Ltd Composition de vaccin combinée pour administration multiple
EP4070815A1 (en) 2016-10-03 2022-10-12 The U.S.A. as represented by the Secretary, Department of Health and Human Services Hiv-1 env fusion peptide immunogens and their use
WO2018081832A1 (en) 2016-10-31 2018-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide fragments from filoviruses and their uses
US11235056B2 (en) 2017-03-24 2022-02-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Glycan-masked engineered outer domains of HIV-1 gp120 and their use
EP3655024A1 (en) 2017-07-18 2020-05-27 Serum Institute of India Private Limited An immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof
US11136356B2 (en) 2017-10-16 2021-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant HIV-1 envelope proteins and their use
WO2020043874A1 (en) 2018-08-31 2020-03-05 Glaxosmithkline Biologicals Sa Conjugated haemophilus influenzae vaccine using bordetella outer membrane vesicle
US20210353740A1 (en) 2018-09-23 2021-11-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Hiv-1 env fusion peptide nanoparticle carrier conjugates and their use
JOP20190242A1 (ar) 2018-10-12 2020-04-12 Serum Institute Of India Pvt Ltd تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها
WO2020086483A1 (en) 2018-10-22 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant gp120 protein with v1-loop deletion
WO2020236973A1 (en) 2019-05-20 2020-11-26 Soligenix, Inc. Compositions and methods of manufacturing trivalent filovirus vaccines
WO2021160887A1 (en) 2020-02-14 2021-08-19 Immunor As Corona virus vaccine
WO2021176409A1 (en) 2020-03-05 2021-09-10 Sanofi Healthcare India Private Limited Preservative combination for vaccine composition
CN117177768A (zh) * 2021-04-20 2023-12-05 Km生物医药股份公司 6种混合液状疫苗的组合物
CA3228275A1 (en) 2021-08-03 2023-02-09 Genoveffa Franchini Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection
EP4169513A1 (en) 2021-10-19 2023-04-26 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising sting agonists
WO2023192835A1 (en) 2022-03-27 2023-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Base-covered hiv-1 envelope ectodomains and their use

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6013718A (ja) * 1983-07-05 1985-01-24 Chemo Sero Therapeut Res Inst Ｂ型肝炎ワクチン
JPS60193925A (ja) * 1984-03-13 1985-10-02 Chemo Sero Therapeut Res Inst 凍結乾燥製剤化ワクチン
US4624918A (en) * 1984-07-09 1986-11-25 Genentech, Inc. Purification process for hepatitis surface antigen and product thereof
FI861417A0 (fi) 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
US4895800A (en) 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
AP56A (en) 1987-01-30 1989-09-26 Smithkline Biologicals S A Hepatitis B virus surface antigens and hybrid antigehs containing them.
EP0304578B1 (en) 1987-06-22 2001-10-24 Medeva Holdings Bv Peptide comprising hepatitis B surface antigen
EP0299108B1 (en) 1987-07-17 1994-05-18 Rhein Biotech Gesellschaft für biotechnologische Prozesse und Produkte mbH DNA-molecules coding for FMDH control regions and structured gene for a protein having FMDH-activity and their uses
JPH085804B2 (ja) * 1988-04-28 1996-01-24 財団法人化学及血清療法研究所 Ａ型及びｂ型肝炎混合アジュバントワクチン
DE69031556T2 (de) 1989-07-25 1998-05-14 Smithkline Beecham Biolog Antigene sowie Verfahren zu deren Herstellung
DE69025375T2 (de) 1989-11-06 1996-08-01 Smithkline Beecham Biolog Verfahren
CY1935A (en) 1990-02-12 1991-02-07 Smithkline Beecham Biolog Novel vaccine and method therefor
GB9007024D0 (en) 1990-03-29 1990-05-30 Imperial College Novel vaccine
AU9052091A (en) * 1990-12-20 1992-07-22 Smithkline Beecham Biologicals (Sa) Vaccines based on hepatitis b surface antigen
CA2067003A1 (en) 1991-04-29 1992-10-30 Peter J. Kniskern Hbsag escape mutant vaccine
JPH06503231A (ja) * 1991-09-18 1994-04-14 アムジエン・インコーポレーテツド 胆汁酸塩を含有するｂ型肝炎ワクチン製剤
EP0812593B8 (en) * 1993-03-23 2010-11-10 SmithKline Beecham Biologicals S.A. Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
PL184872B1 (pl) 1995-06-23 2003-01-31 Smithkline Beecham Biolog Kombinowana szczepionkaĆ zestaw do przygotowania kombinowanej szczepionkiĆ sposób wytwarzania kombinowanej szczepionki i jej zastosowanie
RU2130778C1 (ru) 1998-07-31 1999-05-27 Акционерное общество закрытого типа НПК "Комбиотех Лтд" Комбинированная вакцина для иммунопрофилактики вирусного гепатита в, столбняка, дифтерии и коклюша
KR100385711B1 (ko) 2000-07-05 2003-05-27 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드와 백일해균 및ｂ형간염표면항원을 포함한 4가 혼합백신 및 그 제조방법
KR100401423B1 (ko) 2001-01-10 2003-10-17 주식회사 엘지생명과학 혼합 백신의 제조 방법

Also Published As

Publication number Publication date
SK280702B6 (sk) 2000-06-12
CY2614B2 (en) 2012-01-25
AU709406C (en) 2004-04-08
NO309675B1 (no) 2001-03-12
DE69319728D1 (de) 1998-08-20
JPH07508267A (ja) 1995-09-14
HUT71791A (en) 1996-02-28
CZ289294A3 (en) 1995-09-13
SI9300271A (en) 1993-12-31
SK142194A3 (en) 1995-08-09
EP0835663A3 (en) 1999-03-03
US6013264A (en) 2000-01-11
HK1011290A1 (en) 1999-07-09
EP2156845A1 (en) 2010-02-24
HK1021142A1 (en) 2000-06-02
DE69334297D1 (de) 2009-11-12
ATE168271T1 (de) 1998-08-15
ES2118963T3 (es) 1998-10-01
FI945483A0 (fi) 1994-11-22
EP0642355A1 (en) 1995-03-15
KR100287083B1 (ko) 2001-04-16
AP9300530A0 (en) 1993-07-31
CN1623602A (zh) 2005-06-08
FI945483A (fi) 1995-01-20
DK0835663T3 (da) 2010-02-01
JP3626996B2 (ja) 2005-03-09
AU1648097A (en) 1997-05-29
AU2010200249B2 (en) 2012-01-12
DK0642355T3 (da) 1998-11-30
AU709406B2 (en) 1999-08-26
MY110665A (en) 1999-01-30
CN1085450A (zh) 1994-04-20
EP0642355B1 (en) 1998-07-15
DE122010000016I1 (de) 2010-07-08
MX9302982A (es) 1993-12-01
EP2289548A2 (en) 2011-03-02
UA40596C2 (uk) 2001-08-15
RU94046145A (ru) 1997-03-27
EP0835663B1 (en) 2009-09-30
CN1136918C (zh) 2004-02-04
IL105770A0 (en) 1993-09-22
SG48365A1 (en) 1998-04-17
AU2010200249A1 (en) 2010-02-11
EP2289548A3 (en) 2012-08-08
WO1993024148A1 (en) 1993-12-09
ATE444079T1 (de) 2009-10-15
EP0835663A2 (en) 1998-04-15
LU91659I2 (fr) 2010-05-03
AP567A (en) 1996-11-25
AU2007201162A1 (en) 2007-04-19
HU9403366D0 (en) 1995-02-28
DE69319728T2 (de) 1999-02-04
DE122010000015I1 (de) 2010-07-08
AU785433B2 (en) 2007-05-31
NO944475L (no) 1995-01-18
KR950701822A (ko) 1995-05-17
MA22894A1 (fr) 1993-12-31
CA2136429A1 (en) 1993-12-09
AU4315693A (en) 1993-12-30
NO944475D0 (no) 1994-11-22
CN1313152C (zh) 2007-05-02
CZ283910B6 (cs) 1998-07-15
HU220236B (hu) 2001-11-28
NZ253065A (en) 1996-10-28
IL105770A (en) 1998-08-16
LU91658I2 (fr) 2010-05-03
AU5062902A (en) 2002-08-08
CA2136429C (en) 2001-12-11
RU2160120C2 (ru) 2000-12-10
ES2334181T3 (es) 2010-03-05

Similar Documents

Publication Publication Date Title
HK1021142A1 (en) Combined vaccines comprising hepatitis b surface antigen and other antigens
AU9052091A (en) Vaccines based on hepatitis b surface antigen
AP8800078A0 (en) Hepatitis b virus surface antigens and hybrid antigens containing them
EP0521318A3 (en) Hepatitis c diagnostics and vaccines
IL81920A (en) Vaccines comprising an antigen and interferon-ypsilon and their preparation
NZ224862A (en) Taenia ovis antigens and vaccines
EP0542753A4 (en) Epitopes of the pre-s region of hepatitis b virus surface antigen
GB2238959B (en) Antigen and conjugates thereof for suppressing immune response
IL104291A0 (en) Antigenic epitopes and antibodies against them
AU6769594A (en) Hepatitis c virus immunodiagnostic antigens and antibodies
GB9021286D0 (en) Antigens and antibodies thereto their uses
AU3269793A (en) Method for obtaining recombinant surface antigen of hepatitis B, antigen and vaccine based on it
ZA932210B (en) A process for preparation of a recombinant hepatitis B surface antigen, and antigen and vaccine based thereon
AU3931197A (en) Vaccines and antigenic conjugates
IL104767A0 (en) Antigenic epitopes and antibodies against them
GB8828523D0 (en) St-lt recombinant antigen vaccines
IE871644L (en) T and b cell epitopes of the pre-s region of hepatitis b¹virus surface antigen
GB9212816D0 (en) Vaccines and their uses
BR1100913A (pt) Vacinas combinadas compreendendo o antìgeno superficial da hepatite b e outros antìgenos
IE880458L (en) Virus antigen
ZA944725B (en) Recombinant antigens from mumps virus and their use in vaccines
GB9522485D0 (en) Hepatitis b surface antigen variants